stella
beta
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI — Stella
Recruiting
Back to Non-Small-Cell Lung Cancer trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
China
Shanghai Pulmonary Hospital, Shanghai, Shanghai Municipality
View full record on ClinicalTrials.gov